Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OLMESARTAN MEDOXOMIL vs OLUTASIDENIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OLMESARTAN MEDOXOMIL vs OLUTASIDENIB: Safety Overview

Metric OLMESARTAN MEDOXOMIL OLUTASIDENIB
Total FAERS Reports 11,972 210
Deaths Reported 283 27
Death Rate 2.4% 12.9%
Hospitalizations 6,564 85
Average Patient Age 66.9 yrs 66.2 yrs
% Female Patients 56.6% 46.3%
FDA Approval Date Apr 13, 2020 Dec 1, 2022
Manufacturer direct rx Rigel Pharmaceuticals, Inc.
Route ORAL ORAL
Marketing Status Prescription Prescription